http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone
-
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
-
Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting
-
Sun Pharma Odomzo® (Sonidegib) New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma
-
Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab
-
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
-
Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting
-
Sun Pharma & Moebius Medical Sign Exclusive Global Licensing Deal to Develop Novel Liposomal Non-opioid Pain Product for Osteoarthritis
-
Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoria
-
Sun Pharma Extends Imatinib Mesylate Savings Card Program Benefits for Patients in USA
-
Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis
-
Even Companies Facing Strong Economic Headwinds Can Deliver Superior Shareholder Value
-
Horizon Pharma plc Files Patent Infringement Lawsuits Against Five Companies for Filing Abbreviated New Drug Applications for PENNSAID(R) (Diclofenac Sodium Topical Solution) 2%

